|
Feb 12
|
Positive Market Response in Asia Fuels Potential Revenue Growth for ABVC and BioKey, Marching Into Global Dietary Supplements Market of USD 75.35 Billion
|
|
Jan 2
|
ABVC BioPharma Secures an Additional Patent for ADHD Treatment, in Addition to the Granted U.S. and Australian Patents, Moving Forward to the Global Patent Map of $32.14 Billion Potential Market
|
|
Jun 25
|
ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market
|
|
Jun 12
|
ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue
|
|
May 15
|
Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M
|
|
Feb 15
|
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues
|
|
Feb 8
|
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
|
|
Dec 7
|
ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study
|
|
Dec 5
|
ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials
|
|
Oct 9
|
ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)
|
|
Aug 10
|
ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement
|
|
Aug 7
|
ABVC Corporate Update and CEO's Letter to Shareholders
|
|
Jun 26
|
ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth
|
|
Jun 20
|
ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production
|